Angiotensin II Receptor Blockers for the Treatment of Heart Failure: A Class Effect?

2007 ◽  
Vol 27 (4) ◽  
pp. 526-534 ◽  
Author(s):  
Marie Hudson ◽  
Karin Humphries ◽  
Jack V Tu ◽  
Hassan Behlouli ◽  
Richard Sheppard ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Class Effect ◽  
Angiotensin Ii Receptor ◽  
Receptor Blockers

The Use of Angiotensin-II Receptor Blockers in Heart Failure

2002 ◽  
Vol 15 (4) ◽  
pp. 318-325
Author(s):  
Jodie M. Fink
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Converting Enzyme Inhibitors ◽  
Heart Failure Patients ◽  
Patients With Heart Failure ◽  
Receptor Blockers

Angiotensin-II receptor blockers (ARBs) have recently been evaluated in large trials to determine their role in the treatment of heart failure. It is clear that angiotensin-converting enzyme inhibitors (ACE-Is) prevent the effects of an overactive renin-angiotensin aldosterone system and therefore prevent disease progression. Despite this evidence, intolerance (eg, cough) limits the use of ACE-Is in heart failure patients. Improved tolerability makes ARBs attractive alternatives in patients intolerant to ACE-Is. ARBs are also hypothesized to have additional benefits when used in combination with ACE-Is through more complete inhibition of angiotensin-II. However, studies of ARBs in patients with heart failure have not confirmed this hypothesis. This article describes the rationale and evaluates the literature for the use of ARBs in heart failure.

Sign in / Sign up

Export Citation Format

Share Document